Polyacrylamide hydrogel (PAHG) is a non-toxic, synthetic and non-degradable hydrogel that is biocompatible with the human body. In recent years, it has been used for various indications in many medical fields such as aesthetics, tissue repair, wound healing, cancer and ophthalmic applications. Intra-articular polyacrylamide hydrogel offers promising potential in the musculoskeletal field, especially in providing regeneration and palliative pain in the treatment of osteoarthritis. Osteoarthritis is a common disease in the community, characterized by a pathology involving the entire joint, including cartilage degeneration, bone remodeling, osteophyte formation and synovial inflammation, causing pain, stiffness, swelling and loss of normal joint function. In the treatment of osteoarthritis, both articular cartilage and subchondral bone must heal simultaneously. The best candidate for this would be an agent that can facilitate the healing or regeneration of two tissues together. European approval for the treatment of PAHG in symptomatic advanced knee osteoarthritis was granted in 2021. Studies conducted after this period emphasize that PAHG treatment reduces pain and stiffness by integrating into the synovial tissue, creating a buffer-like effect, and may reduce the need for surgery. We wanted to present PAHG treatment, which is a very new treatment method in the treatment of osteoarthritis, in the light of current literature.